MARKET

MREO

MREO

MEREO BIOPHARMA
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.435
+0.215
+9.68%
Closed 16:00 11/19 EST
OPEN
2.238
PREV CLOSE
2.220
HIGH
2.600
LOW
2.230
VOLUME
14.03K
TURNOVER
--
52 WEEK HIGH
8.48
52 WEEK LOW
2.180
MARKET CAP
52.95M
P/E (TTM)
-1.1169
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of MREO and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

MREO News

  • Mereo BioPharma’s Setrusumab Demonstrates Dose-Dependent Bone Building and Trend in Fracture Reduction in Phase 2b ASTEROID Study in Adults with Osteogenesis Imperfecta
  • GlobeNewswire.11/11 11:30
  • 55 Biggest Movers From Yesterday
  • Benzinga.10/11 10:28
  • BBBY, FSCT, PCG and RARX among midday movers
  • Seeking Alpha - Article.10/10 16:38
  • Jefferies softens view on UnitedHealth in premarket analyst action
  • Seeking Alpha - Article.10/10 12:46

More

Industry

Biotechnology & Medical Research
+2.16%
Pharmaceuticals & Medical Research
+0.78%

Hot Stocks

Name
Price
%Change

About MREO

Mereo BioPharma Group PLC is a United Kingdom-based biopharmaceutical company. The Company is focused on development and commercialization of therapeutics for patients with rare diseases. Its pipeline includes BPS-804, MPH-966, BCT-197, BGS-649, Navicixizumab and Etigilimab. BPS-804 (setrusumab) is being developed to improve bone strength and thereby reduce fractures in the orphan disease osteogenesis imperfecta (OI). MPH-966 (alvelestat) is being developed for alpha-1 antitrypsin deficiency (AATD). BGS-649 (leflutrozole) is being developed for the treatment of obese men with hypogonadotropic hypogonadism (HH). BCT-197 (acumapimod) is being developed as a therapy for acute exacerbations of chronic obstructive pulmonary disease (AECOPD). Navicixizumab is being developed for platinum-resistant ovarian cancer. Etigilimab is being developed for advanced or metastatic solid tumors.
More

Webull offers Mereo BioPharma Group PLC (MREO) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.